RE:False starts?The last few days have seen a small version of what I've always called Stoopid Dayz, where the stock runs for no real reason other than people think it's on a run and so they buy until too many people see it as a chance to sell.
As far as "followthru" is concerned, I think news will come in its own good time. Share price follows news, generally not the other way around.
As I move away from Bioasis, I have two questions that I'd like to see answered.
1. The capabilities of xB3
With such high numbers of LRP-1 receptors in the brain, is xB3 seriously limited in the number of payloads it can carry into the brain without causing toxic responses due to too many of the xB3-drugs' payloads going off target to LRP-1 receptors and not to the payloads' intended receptors. Phrased another way, is xB3 limited in the number of diseases it can treat? Are deals hard to do because of a perceived (or actual) LRP-1 problem?
2. The capabilities of Bioasis management to make deals.
Whether or not xB3 has off-target problems, is the Bioasis management capable of making deals of high value for the diseases that can be treated with xB3 drugs? Even if low upfront payments seem inevitable for the first deal or two, there is no good reason for milestone payments to not reflect the value of effective treatment of any disease. Milestones are meant to mitigate risk but the milestone payment amounts should be set in accordance with the value of success. Success should bring high value to both Bioasis and its partners and not just to the partner.
After 14 years, it's time that xB3 be proven, and that it's done in a public manner. My guess is that drugs like Enhertu cannot be delivered to the brain by xB3 because it would kill too many healthy brain cells. LSDs may be different, that the delivery of the missing enzymes to the LRP-1 receptor would not be especially toxic, that the delivered drug could be handled by the body's own collection and disposal methods.
And, it's possible that Bioasis could discover and utilize a linker that could dissociate xB3 from its payload before it can find its way to the LRP-1 receptor. That would leave the payload free to find its own receptor, channel or whatever target for which it is intended.
Ok, I think I should shut down at this point. This forum is too much of a distraction for me and I have funner stuff to do. I may watch but I won't have much more to say, if anything, about Bioasis in the future.
Good luck, everybody. Thanks for your support over the years.
jd